NanoViricides Inc., a clinical stage company specializing in the development of broad-spectrum antivirals, has announced the potential of its drug candidate NV-387 to address the increasing global cases of measles. NV-387 has shown effectiveness and safety in animal model studies, specifically in humanized h-CD150+ knock-in mice, and has completed a Phase I clinical trial with no adverse events reported. The company is considering pursuing a "Fast Track" designation for NV-387, which could expedite its approval process. Measles is categorized as a rare orphan disease in the USA, potentially qualifying NV-387 for Orphan Drug Designation, offering benefits such as tax credits and market exclusivity. There is currently no approved drug for the treatment of measles. The results of the NV-387 studies have already been presented by NanoViricides.